Dr Reddy's Q1 FY27 Net Profit Falls 69% Amid Lower US Sales and Semaglutide Provision
Dr Reddy's Laboratories reported a 69% year-on-year decline in consolidated net profit to around Rs 443 crore for Q1 FY27, primarily due to lower sales of the cancer drug lenalidomide and a Rs 240 crore provision related to quality issues with the semaglutide active pharmaceutical ingredient. Consolidated revenue fell about 5.5-6% to approximately Rs 8,070 crore, with North American sales dropping over 35%. Despite these setbacks, the company’s base business showed double-digit growth across other key markets, supported by new product launches and favorable currency movements.
First-hand measurement across 9 sources
We measured how 9 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (44/100). Lens Score 36/100.
Outlets measured: mint, thehindu, businessstandard, businessstandard, news18, businessstandard, freepressjournal, thefinancialexpress, and 1 more. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (35–52/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
republicworld broke this story on 22 Jul, 11:21 am. Other outlets followed.